Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 623

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 623
---
3 |     | $                            | 903,548 |     | $                | 389,840 |     | $              | (328,111 | ) |     | $                        | 185,598 |
| 2022 |     | $                            | 911,088 |     | $                | 287,648 |     | $              |  102,900 |   |     | $                        | 726,340 |

| (5) | Total Shareholder Return (“TSR”): Cumulative TSR is calculated by dividing the sum of the                                                                                                                                                     
 cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between Kineta’s share price at the end and the beginning of the measurement period by Kineta’s share price at the beginning of 
 the measurement period.                                                                                                                                                                                                                       |

| (6) | Net Loss: The dollar amounts reported represent the amount of net loss reflected in Kineta’s audited 
 financial statements for the applicable year.                                                        |

414

Analysis of the Information Presented in the Pay versus Performance Table

Kineta’s executive compensation program reflects a variable
pay-for-performance philosophy. While Kineta utilizes various performance measures to align executive compensation with company performance, all of those company
measures are not presented in the Pay versus Performance table. Moreover, Kineta generally seeks to incentivize long-term performance, and therefore does not specifically align Kineta’s performance measures with compensation that is actually
paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, Kineta is providing the
following descriptions of the relationships between information presented in the Pay versus Performance table.

Compensation Actually Paid and Cumulative TSR

The following graph demonstrates the relationship of the amount of compensation actually paid to Dr. Iadonato and
Dr. Peters and the average amount of compensation actually paid to Kineta’s NEOs as a group (excluding Dr. Iadonato and Dr. Peters) with Kineta’s cumulative TSR over the three years presented in the table.

415

Compensation Actually Paid and Net Loss

Kineta has incurred significant losses to date, and Kineta’s ability to generate product revenue sufficient to achieve profitability will
depend on the successful development and eventual commercialization of one or more of Kineta’s current and future product candidates. The table below demonstrates the relationship between the amount of compensation actually paid to
Kineta’s PEO and the average